• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞减灭性肾切除术治疗转移性肾细胞癌的死亡率和发病率:一项基于人群的研究。

Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study.

机构信息

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.

出版信息

Ann Surg Oncol. 2011 Oct;18(10):2988-96. doi: 10.1245/s10434-011-1715-2. Epub 2011 Apr 16.

DOI:10.1245/s10434-011-1715-2
PMID:21499808
Abstract

PURPOSE

To test whether the rates of in-hospital mortality, complications, and transfusions are higher in patients treated with cytoreductive nephrectomy (CNT) for metastatic renal cell carcinoma (mRCC) relative to patients treated with nephrectomy (NT) for non-mRCC.

METHODS

We assessed 17,688 patients treated with a NT between years 1999 and 2008, within the Florida Inpatient Database. Chi-square and Student t-tests were used to compare the statistical significance of differences in proportions and means, respectively. Univariable and multivariable logistic regression analyses tested the relationship between surgery type (CNT vs. NT) and three end points: in-hospital mortality, complications, and transfusions.

RESULTS

Overall, 6.0% of patients underwent CNT. The rates of in-hospital mortality, complications, and transfusions were 2.4, 26.5, and 24.3% in CNT patients versus 0.9, 18.9, and 11.1% in NT patients. At multivariable analyses, CNT patients demonstrated a 2.0-, 1.3-, and 2.4-fold higher risk of in-hospital mortality, complications, and transfusions (all P < 0.001). Similarly, more advanced age, comorbidity, and the cumulative number of secondary surgical procedures were independent predictors of a higher risk of in-hospital mortality, complications, and transfusions (all P < 0.001).

CONCLUSIONS

The rate of in-hospital mortality, complications, and transfusions is higher in patients treated with CNT relative to NT. Older age, higher comorbidity, and the necessity of secondary surgical procedures further increases the risk of all aforementioned end points. Physicians should consider these observations during the planning of a CNT, and patients should be informed accordingly.

摘要

目的

检测细胞减灭性肾切除术(CNT)治疗转移性肾细胞癌(mRCC)患者与肾切除术(NT)治疗非 mRCC 患者的住院死亡率、并发症和输血率是否更高。

方法

我们评估了 1999 年至 2008 年期间佛罗里达州住院患者数据库中 17688 例接受 NT 治疗的患者。卡方检验和学生 t 检验分别用于比较比例和均值的统计学意义。单变量和多变量逻辑回归分析测试了手术类型(CNT 与 NT)与三个终点之间的关系:住院死亡率、并发症和输血。

结果

总体而言,有 6.0%的患者接受了 CNT。CNT 患者的住院死亡率、并发症和输血率分别为 2.4%、26.5%和 24.3%,而 NT 患者分别为 0.9%、18.9%和 11.1%。在多变量分析中,CNT 患者的住院死亡率、并发症和输血风险分别增加了 2.0 倍、1.3 倍和 2.4 倍(均 P < 0.001)。同样,年龄较大、合并症和累计二次手术数量是住院死亡率、并发症和输血风险增加的独立预测因素(均 P < 0.001)。

结论

与 NT 相比,CNT 治疗的患者住院死亡率、并发症和输血率更高。年龄较大、合并症更多以及需要二次手术会进一步增加所有上述终点的风险。医生在计划 CNT 时应考虑这些观察结果,并相应地告知患者。

相似文献

1
Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study.细胞减灭性肾切除术治疗转移性肾细胞癌的死亡率和发病率:一项基于人群的研究。
Ann Surg Oncol. 2011 Oct;18(10):2988-96. doi: 10.1245/s10434-011-1715-2. Epub 2011 Apr 16.
2
Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.终末期肾病患者行肾切除术治疗非转移性肾癌的围手术期发病率和住院死亡率更高:一项基于人群的分析。
BJU Int. 2012 Sep;110(6 Pt B):E183-90. doi: 10.1111/j.1464-410X.2012.10936.x. Epub 2012 Feb 9.
3
Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.转移性肾细胞癌患者接受减瘤性肾切除术与未接受手术的基于人群的生存评估。
Urology. 2009 Feb;73(2):342-6. doi: 10.1016/j.urology.2008.09.022. Epub 2008 Nov 28.
4
Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.老年人群行细胞减灭性肾切除术:来自美国的一项基于人群的队列研究。
BJU Int. 2012 Jun;109(12):1807-12. doi: 10.1111/j.1464-410X.2011.10569.x. Epub 2011 Sep 27.
5
Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: a national series.开放性与腹腔镜肾部分切除术的并发症、输血、住院时间和院内死亡率的倾向评分匹配比较:一项全国性系列研究。
Eur J Surg Oncol. 2012 Jan;38(1):80-7. doi: 10.1016/j.ejso.2011.09.035. Epub 2011 Oct 13.
6
In-hospital mortality and failure to rescue after cytoreductive nephrectomy.细胞减灭性肾切除术治疗后的住院死亡率和未能抢救成功。
Eur Urol. 2013 Jun;63(6):1107-14. doi: 10.1016/j.eururo.2012.08.069. Epub 2012 Sep 7.
7
A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States.美国转移性肾细胞癌减瘤性肾切除术发生率的基于人群的分析。
Urology. 2009 Oct;74(4):837-41. doi: 10.1016/j.urology.2009.04.019. Epub 2009 Jul 18.
8
The relationship of postoperative complications with in-hospital outcomes and costs after renal surgery for kidney cancer.肾细胞癌患者术后并发症与住院结局和费用的关系。
BJU Int. 2013 Apr;111(4):580-8. doi: 10.1111/j.1464-410X.2012.11122.x. Epub 2012 May 7.
9
Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.非透明细胞组织学类型的转移性肾细胞癌的减瘤性肾切除术。
J Urol. 2007 Nov;178(5):1896-900. doi: 10.1016/j.juro.2007.07.037. Epub 2007 Sep 17.
10
Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective.淋巴结侵犯对转移性肾细胞癌患者预后的意义:基于人群的观点。
Cancer. 2009 Dec 15;115(24):5680-7. doi: 10.1002/cncr.24682.

引用本文的文献

1
Management of Metastatic Renal Cell Carcinoma in a Tertiary Care Hospital.三级医疗中心转移性肾细胞癌的管理
Cureus. 2023 Feb 28;15(2):e35623. doi: 10.7759/cureus.35623. eCollection 2023 Feb.
2
The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes.细胞减灭性肾切除术对接受免疫治疗的转移性肾细胞癌患者生存结局的影响:基于证据的比较结局分析。
Front Immunol. 2023 Mar 14;14:1132466. doi: 10.3389/fimmu.2023.1132466. eCollection 2023.
3
Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database.
转移性肾癌患者能从减瘤性肾切除术中获益吗?一项基于监测、流行病学和最终结果(SEER)数据库的真实世界回顾性研究。
Front Surg. 2021 Aug 30;8:716455. doi: 10.3389/fsurg.2021.716455. eCollection 2021.
4
Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis.减瘤性肾切除术联合靶向治疗转移性肾细胞癌的长期生存结果:一项系统评价和个体患者数据荟萃分析
Cancers (Basel). 2021 Feb 9;13(4):695. doi: 10.3390/cancers13040695.
5
The role of open radical nephrectomy in contemporary management of renal cell carcinoma.开放性根治性肾切除术在当代肾细胞癌治疗中的作用。
Transl Androl Urol. 2020 Dec;9(6):3123-3139. doi: 10.21037/tau-19-327.
6
Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?减瘤性肾切除术仍是转移性肾细胞癌的治疗标准吗?
J Kidney Cancer VHL. 2019 Mar 5;6(1):1-7. doi: 10.15586/jkcvhl.2019.114. eCollection 2019.
7
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.一项立体定向消融放疗(SABR)作为不可切除转移性肾细胞癌患者细胞减灭性肾切除术替代治疗的前瞻性 I 期剂量递增试验。
Radiat Oncol. 2018 Mar 20;13(1):47. doi: 10.1186/s13014-018-0992-3.
8
Current Management Options in Metastatic Renal Cell Cancer.转移性肾细胞癌的当前管理选择
Oncol Rev. 2017 Jun 14;11(2):339. doi: 10.4081/oncol.2017.339.
9
Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.现代减瘤性肾切除术:使用、发病率及生存的预测因素
Can Urol Assoc J. 2017 May;11(5):E184-E191. doi: 10.5489/cuaj.4137. Epub 2017 May 9.
10
Comparison of the Clinical Efficacy of Retroperitoneal Laparoscopic Partial Nephrectomy and Radical Nephrectomy for Treating Small Renal Cell Carcinoma: Case Report and Literature Review.后腹腔镜下肾部分切除术与根治性肾切除术治疗小肾癌的临床疗效比较:病例报告与文献复习
Iran Red Crescent Med J. 2016 Jul 18;18(10):e23912. doi: 10.5812/ircmj.23912. eCollection 2016 Oct.